Biocon per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹3.40₹2.82₹8.46₹8.55₹3.88
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹3.38₹2.82₹8.46₹8.54₹3.87
₹209.94₹209.94₹180.28₹164.78₹148.82
₹106.85₹104.42₹127.12₹122.90₹93.07
—₹12.30₹33.83₹24.60₹15.43
₹0.51₹0.51₹14.31₹8.51₹1.05
—₹0.56₹0.69₹1.69₹0.60
162.1162.1120.1120.1120.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BIOCON₹350.70

Biocon Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYSYNGENEMANKINDGLENMARKLAURUSLABSALKEMLUPINMcap ₹56,848 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS3.888.558.462.823.40
Diluted EPS3.878.548.462.823.38
Book Value per Share148.82164.78180.28209.94209.94
Revenue per Share93.07122.90127.12104.42106.85
Cash Flow per Share15.4324.6033.8312.30—
Free Cash Flow per Share1.058.5114.310.510.51
Dividends per Share0.601.690.690.56—
Shares Outstanding (cr)120.1120.1120.1162.1162.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.